Implanet announced it has received CE mark to market the JAZZ Passer, a band that allows surgeons to work around anatomical structures, according to a company release.
In September, Implant received FDA 510 (k) clearance to market the device in the United States.
“This innovation will accelerate the adoption of JAZZ technology by new European surgeons,” Ludovic Lastennet, chief executive officer of Implanet, said in the release. “This highly dynamic market is driven by France and Germany, regions where we are active, notably in the high potential adult degenerative bone disorder segment. At the recent Eurospine conference in Dublin, we saw enthusiasm for our solution from health professionals and surgeons. We were able to show, during a thematic evening with more than 50 participants and throughout this conference, how easy to use our latest innovations are.”